Last modified: 2022-09-16
Abstract
Background:
Gastric cancer (GC) with peritoneal metastases is conventionally considered a terminal stage of the disease. Currently standard care of these patients is palliative Chemotherapy only. The goal of this study is to evaluate the role of CRS & HIPEC in these patients.
Methodology:
Data of all patients diagnosed with GC with peritoneal metastases who underwent CRS and HIPEC was retrieved from a prospectively maintained electronic data base. Disease free survival (DFS) and overall survival (OS) were calculated using Kaplan Meier survival analysis.
Results:
During the study period(2015 - 2022) 13 patients of GC with peritoneal metastasis underwent CRS HIPEC. Median PCI score was 3. There was no post-operative mortality. At a median follow up of 16months, median DFS was 16months and median OS was 21months.
Conclusions:
CRS and HIPEC can improve long term outcomes in patients of gastric cancer with limited peritoneal metastasis.